Opexa Tovaxin drug receives FDA fast-track designation

10th November 2011 (Last Updated November 10th, 2011 18:30)

The US Food and Drug Administration (FDA) has granted fast-track designation to Opexa Therapeutics' Tovaxin drug candidate, used to treat secondary progressive multiple sclerosis.

The US Food and Drug Administration (FDA) has granted fast-track designation to Opexa Therapeutics' Tovaxin drug candidate, used to treat secondary progressive multiple sclerosis.

The fast-track status will facilitate to develop and expedite the review of drugs intended to treat serious or life-threatening conditions.

Fast-track priority review products are expected to be approved during the first review cycle, resulting in a halved review period compared to those without the designation.

Opexa president and CEO Neil Warma said the receipt of fast-track designation will advance Tovaxin through the clinical and regulatory process.